Open AccessComparison of the Effects of Liraglutide on Islet Graft Survival Between Local and Systemic Delivery
Author(s) -
Song Mi Lee,
Donghee Kim,
Kyung Min Kwak,
Phyu Phyu Khin,
Oh Kyung Lim,
Kwang-Won Kim,
Byung-Joon Kim,
Hee-Sook Jun
Publication year - 2020
Publication title -
cell transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.043
H-Index - 100
eISSN - 1555-3892
pISSN - 0963-6897
DOI - 10.1177/0963689720971245
Subject(s) - liraglutide , islet , transplantation , medicine , diabetes mellitus , renal capsule , endocrinology , streptozotocin , glucagon like peptide 1 , type 2 diabetes
Islet transplantation has emerged as a promising treatment for type 1 diabetes mellitus. Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, protects beta cells after islet transplantation by improving glycemic control through several mechanisms. In this study, we compared the effects of local pretreatment and systemic treatment with liraglutide on islet transplantation in a diabetic mouse model. Streptozotocin (STZ)-induced diabetic C57BL/6 mice were transplanted with syngeneic islets under the kidney capsule. Isolated islets were either locally treated with liraglutide before transplantation or mice were treated systemically by intraperitoneal injection after islet transplantation. Local pretreatment of islets with liraglutide was more effective in increasing body weight, decreasing hemoglobin A1c levels, and lowering blood glucose levels in STZ-diabetic mice transplanted with islets. Local pretreatment was also more effective in increasing insulin secretion and islet survival in STZ-diabetic mice. Histological analysis of the transplantation site revealed fewer apoptotic cells following local pretreatment compared with systemic injection of liraglutide. These findings indicate that liraglutide administered once locally before transplantation might have superior effects on islet preservation than systemic administration.